CN109200044A - A kind of taxol and dibenzo [b, d] thiophene-based STAT inhibitor tartrate drug combination compositions - Google Patents
A kind of taxol and dibenzo [b, d] thiophene-based STAT inhibitor tartrate drug combination compositions Download PDFInfo
- Publication number
- CN109200044A CN109200044A CN201811283138.1A CN201811283138A CN109200044A CN 109200044 A CN109200044 A CN 109200044A CN 201811283138 A CN201811283138 A CN 201811283138A CN 109200044 A CN109200044 A CN 109200044A
- Authority
- CN
- China
- Prior art keywords
- formula
- compound
- thiophene
- tartrate
- dibenzo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Abstract
The present invention provides a kind of taxols and dibenzo [b, d] thiophene-based STAT inhibitor tartrate drug combination compositions, include active constituent and pharmaceutically acceptable auxiliary material, active constituent dibenzo [b as shown in taxol and formula (I), d] thiophene-based STAT inhibitor tartrate composition, the mass ratio of dibenzo [b, d] thiophene-based STAT inhibitor tartrate shown in taxol and formula (I) is (0.09-0.21) in the active constituent: 1.The composition mesotartrate good water solubility, bioavilability are high, stability is good.
Description
Technical field
The invention belongs to field of medicinal chemistry, be related to dibenzo [b, d] thiophene-based STAT3 inhibitor tartrate and its
Preparation method and purposes, in particular it relates to 4- (dibenzo [b, d] thiophene -4- base) -6- (4- acrylyl aminobenzene
Base)-N- (2- methyl -4H- chromene -4- ketone group) -1,3,5- triazine -2- amine tartrate and preparation method thereof and purposes.
Background technique
Cancer is the general designation of a major class malignant tumour, its main feature is that without limitation, without end hyperplasia.Cancer cell makes patient's body
Interior nutriment is largely consumed, while releasing a variety of toxin, and human body is made to generate a series of symptoms, cause human body it is thin,
Inability, anaemia, loss of appetite, fever and serious organ function are impaired, cause necrotic hemorrhage concurrent infection, patient finally by
It is dead in organ failure.
Signal transduction and (the Signal Transducer and Activator of of activating transcription factor -3
Transcription-3, STAT3) be a kind of GAP-associated protein GAP that can be activated by different cytokine receptors, cell because
Carrier is served as during son-acceptor interaction, the inherence specificity for keeping signal to transmit in the cell, and pass through induction target
The effect effect of biostimulation is expressed in genetic transcription, other than participating in angiogenesis and immune response, also with the increasing of cell
It grows, survive, breaking up, the close associations such as anti-apoptotic.STAT3 is in kinds of tumor cells (including blood such as leukaemia, Huppert's disease
A variety of entity tumors such as liquid tumour and lung cancer, breast cancer, prostate cancer) in abnormal expression increase, generation with malignant tumour,
Develop closely related.
By inhibiting STAT3 activity to be expected to that cancer cell is made apoptosis occur to achieve the purpose that treating cancer, study recently
It was found that inhibiting STAT3 signal that can overcome the chemical drug resistance including kinds of tumors such as retinoblastoma, lung cancer, leukaemia
Property, successfully research and development are a new antitumor target to STAT3.Therefore, new STAT3 inhibitor is actively found for cancer
Treatment have particularly important meaning.
The chemical name of compound (I) is 4- (dibenzo [b, d] thiophene -4- base) -6- (4- allyl amido phenyl)-N-
(2- methyl -4H- chromene -4- ketone group) -1,3,5-triazines -2- amine, cell in vitro Activity determination find it to prostate gland cancer cell
DU-145 and human breast cancer cell MDA-MB-468 has excellent inhibitory activity, to the IC of prostate gland cancer cell DU-14550Value
For 10.2nM, to the IC of human breast cancer cell MDA-MB-46850Value is 4.8nM, is had a good application prospect.But in compound
(I) in druggability research process, the inventors found that different compound (I) pharmaceutical salts are in water-soluble, biological utilisation
Degree etc. has biggish difference.Therefore, further investigation, which is found, is suitble to medicinal 4- (dibenzo [b, d] thiophene -4- base) -6-
(4- allyl amido phenyl)-N- (2- methyl -4H- chromene -4- ketone group) -1,3,5-triazines -2- amine salt type, it is very necessary.
Summary of the invention
On the one hand, the present invention provides a kind of taxols and dibenzo [b, d] thiophene-based STAT inhibitor tartrate to join
Combination with medication composition includes active constituent and pharmaceutically acceptable auxiliary material, and the active constituent is by taxol and formula (I)
Shown in dibenzo [b, d] thiophene-based STAT inhibitor tartrate composition, in the active constituent shown in taxol and formula (I)
Dibenzo [b, d] thiophene-based STAT inhibitor tartrate mass ratio be (0.08-0.14): 1；Wherein, shown in formula (I)
Dibenzo [b, d] thiophene-based STAT inhibitor tartrate, chemical formula are as follows:
Preferably, the present invention provides 4- (dibenzo [b, d] thiophene -4- base) -6- (4- allyl amido phenyl)-N- (2-
Methyl -4H- chromene -4- ketone group) -1,3,5-triazines -2- amine tartrate preparation method, comprising the following steps:
The compound of formula (1) is made in step a:2- hydroxy acetophenone acetylation；
Step b: the compound of formula (2) is made in the compound cyclization of formula (1)；
Step c: the compound of formula (3) is made in the compound bromo of formula (2)；
Step d: the compound amino of formula (3) replaces the compound that formula (4) are made；
The compound of formula (5) is made in step e:4- nitrobenzene methyl and biuret cyclization；
Step f: the compound of formula (6) is made in the compound chloro of formula (5)；
Step g: the compound of formula (6) reacts the compound that formula (7) are made with the compound of formula (4)；
Step h: the compound and 4- (4,4,5,5- tetramethyl -1,3,2- dioxolane borine) -9- oxo-of formula (7)
9H- thioxanthene reacts the compound that formula (8) are made；
Step i: the compound reduction of formula (8) hydrogenates the compound that formula (9) are made；
Step j: the compound of formula (9) reacts the compound that formula (I) is made with acryloyl chloride；
Step k: the compound of formula (I) is reacted with tartaric acid is made formula (I) compound tartrate, and reaction route is as follows:
In some preferred embodiments, the solvent that formula (I) compound is reacted with tartaric acid be selected from alcohol, ketone or they
Mixture；In a further preferred embodiment, the solvent that formula (I) compound is reacted with tartaric acid is selected from methanol, ethyl alcohol, third
Ketone or their mixture；In embodiment still more preferably, the solvent that formula (I) compound is reacted with tartaric acid is first
Alcohol or ethyl alcohol.
In some preferred embodiments, the molar ratio that formula (I) compound is reacted with tartaric acid is about 1:0.5-0.55；
In a further preferred embodiment, the molar ratio that formula (I) compound is reacted with tartaric acid is about 1:0.5.
In some specific embodiments, formula (I) compound and tartaric acid are in etoh solvent, according to formula (I) chemical combination
The molar ratio of object and tartaric acid is 1:0.5, and back flow reaction 0.5-1h to obtain the final product.
4- (dibenzo [b, d] thiophene -4- base) -6- (4- allyl amido phenyl)-N- (2- methyl -4H- color of the invention
Alkene -4- ketone group) -1,3,5- triazine -2- amine tartrate, taxol and pharmaceutically acceptable carrier, diluent or excipient
It is prepared by mixing into pharmaceutical preparation, to be suitable for oral or parenteral.Medication includes, but are not limited to intradermal, intramuscular, abdomen
In film, intravenous, subcutaneous, intranasal and peroral route.The preparation can be applied by any approach, such as by being transfused or pushing away
Note is applied by the approach that transepithelial or mucocutaneous (such as oral mucosa or rectum etc.) absorb.Administration can be whole body
Or part.The example of oral administration preparation includes solid or liquid dosage form, specifically, including tablet, pill, granula, powder
Agent, capsule, syrup, emulsion, suspension etc..The preparation can be prepared by methods known in the art, and include drug system
The conventional use of carrier in agent field, diluent or excipient.
The present invention also provides a kind of combinations of dibenzo [b, d] thiophene-based STAT inhibitor tartrate combination medicine
Object includes active constituent and pharmaceutically acceptable auxiliary material, and the active constituent is shown in taxol, lenalidomide, formula (I)
Dibenzo [b, d] thiophene-based STAT inhibitor tartrate composition, in the active constituent two shown in taxol and formula (I)
The mass ratio of benzo [b, d] thiophene-based STAT inhibitor tartrate is (0.08-0.14): (0.08-0.12): 1.
Specific embodiment
The present invention is explained in more detail with reference to embodiments, the embodiment of the present invention is merely to illustrate technology of the invention
Scheme not limits the scope of the invention.
The preparation of 1 2- aminomethyl -4H- chromene -4- keto hydrochloride of embodiment
The preparation of step 1 2- acetoxy acetophenone
2- hydroxy acetophenone (100mmol), chloroacetic chloride (250mmol) and potassium carbonate (500mmol) are added in reaction flask,
300ml acetone is added, back flow reaction 12h, after reaction, water, ethyl acetate extraction, anhydrous sulphur is added in evaporating solvent under reduced pressure
Sour sodium is dry, is concentrated to give grease, directly throws in next step.
The preparation of step 2 2- methyl -4H- chromene -4- ketone
2- acetoxy acetophenone (50mmol) is weighed in reaction flask, 100ml DMSO is added and dissolves, at 0-5 DEG C in batches
It is added sodium hydrogen (150mmol), finishes, be warmed to room temperature stirring 3h and water, dilute hydrochloric acid tune pH are added into reaction solution after reaction
It is worth faintly acid, ethyl acetate extraction, anhydrous sodium sulfate is dry, is concentrated to give grease, and 100ml second is added into gained grease
Acid and 5 drop concentrated hydrochloric acids, back flow reaction about 3h, reaction terminate, reaction solution are spin-dried for, and water, ethyl acetate extraction, anhydrous slufuric acid is added
Sodium is dry, and column chromatographic purifying obtains title compound.
ES:M/Z 161 [M+H]+。
The preparation of step 3 2- bromomethyl -4H- chromene -4- ketone
By step 2 gained 2- methyl -4H- chromene -4- ketone (10mmol), N-bromosuccinimide (NBS, 10mmol) and
Benzoyl peroxide (BPO, 0.95mmol) is added in reaction flask, and 20ml carbon tetrachloride is added to dissolve, back flow reaction 12h, reaction knot
Shu Hou, reaction solution add water, and ethyl acetate extraction, anhydrous sodium sulfate is dry, and column chromatographic purifying obtains title compound.
ES:M/Z 239 [M+H]+。
The preparation of step 4 2- aminomethyl -4H- chromene -4- keto hydrochloride
Step 3 gained 2- bromomethyl -4H- chromene -4- ketone (0.5mmol) is added in reaction flask, it is molten that 5ml DMF is added
Solution is added 2ml ammonium hydroxide, 12h is stirred at room temperature, and after reaction, water, ethyl acetate extraction is added in reaction solution, and anhydrous sodium sulfate is done
Dry, filtering is spin-dried for, and ethyl acetate 5ml is added, and the ethyl acetate hydrogen chloride solution of saturation is added after stirring and dissolving to supernatant layer nothing
Precipitating generates, and filters, dry, obtains title compound.
ES:M/Z 239 [M+H]+。
The preparation of chloro- 6- (4- the nitrobenzophenone) -1,3,5- triazine of 2 2,4- of embodiment bis-
The preparation of step 1 4- nitrobenzene methyl
4- nitrobenzoic acid (250mmol) is weighed in reaction flask, the dissolution of 300mL methanol is added, thionyl chloride is added dropwise
(375mmol) drips and finishes back flow reaction 12h, and after reaction, decompression is spin-dried for, and saturated sodium bicarbonate solution is added and adjusts pH to 7-
8, ethyl acetate extraction, anhydrous sodium sulfate is dry, is concentrated to give title compound, directly throws in next step.
The preparation of step 2 6- (4- nitrobenzophenone) -1,3,5- triazine -2,4- (1H, 3H)-diketone
Biuret (100mmol) is weighed in reaction flask, the dissolution of 150mL glycol dimethyl ether is added, adds in batches at 0-5 DEG C
Enter sodium hydride (83.4mmol), finish, be stirred to react 1h at 50 DEG C, adds 4- nitrobenzene methyl (83.4mmol), add
Finish, be warming up to 85 DEG C of reaction 20h and be after reaction poured into water reaction solution, adjusts pH to acidity with concentrated hydrochloric acid, filter, filter
Cake drying, obtains title compound.
ES:M/Z 235 [M+H]+。
The preparation of step 3 2,4- bis- chloro- 6- (4- nitrobenzophenone) -1,3,5- triazine
6- (4- nitrobenzophenone) -1,3,5-triazines -2,4- (1H, 3H)-diketone (200mmol) is added in reaction flask, is added
Entering 200mL phosphorus oxychloride, phosphorus pentachloride (800mmol), reaction solution is poured into water by 105 DEG C of reaction 12h after reaction, and two
Chloromethanes extraction, anhydrous sodium sulfate is dry, is concentrated to give title compound.
ES:M/Z 275 [M+H]+。
The chloro- 6- of 3 4- of embodiment (4- nitrobenzophenone)-N- (2- methyl -4H- chromene -4- ketone group) -1,3,5- triazine -2- amine
Preparation
Chloro- 6- (4- the nitrobenzophenone) -1,3,5- triazine (50mmol) of 2 gains 2,4- of embodiment bis- is weighed in reaction flask
In, the dissolution of 100mL tetrahydrofuran is added, 1 gains 2- aminomethyl -4H- chromene -4- keto hydrochloride 2- (trifluoro of embodiment is added
Methyl)-pyridine -4- amine (55mmol), sodium carbonate (100mmol), back flow reaction 72h, filtering, column chromatographic purifying obtains title compound
Object.
ES:M/Z 416 [M+H]+。
4 4- of embodiment (dibenzo [b, d] thiophene -4- base) -6- (4- allyl amido phenyl)-N- (2- methyl -4H- color
Alkene -4- ketone group) -1,3,5- triazine -2- amine preparation
The preparation of step 1 4- (4,4,5,5- tetramethyl -1,3,2- dioxolane borine) -9- oxo -9H- thioxanthene
Weigh the bromo- dibenzo of 2- [b, d] thiophene (1mmol), connection pinacol borate (1.1mmol), potassium acetate (2mmol)
With 1,1'- bis(diphenylphosphino) ferrocene dichloropalladium (Pd (dppf) Cl2, 2mmol) and in reaction flask, 5mL Isosorbide-5-Nitrae-two is added
Six ring of oxygen, for 24 hours, after reaction, water is added in 100 DEG C of reactions under the conditions of nitrogen protection, and ethyl acetate extraction merges organic phase,
Saturated common salt water washing merges organic phase, dries, filters, and is concentrated, and column chromatographic purifying obtains title compound.
ES:M/Z 311 [M+H]+。
Step 24- (dibenzo [b, d] thiophene -4- base) -6- (4- nitrobenzophenone)-N- (2- methyl -4H- chromene -4- ketone
Base) -1,3,5- triazine -2- amine preparation
In 30ml microwave reaction bottle, embodiment 3 gained mixture 4- chloro- 6- (4- nitrobenzophenone)-N- (2- is sequentially added
Methyl -4H- chromene -4- ketone group) -1,3,5- triazine -2- amine (10mmol), step 1 gains 4- (tetramethyl -1 4,4,5,5-,
3,2- dioxolane borine) -9- oxo -9H- thioxanthene (10mmol), [bis- (diphenylphosphine) ferrocene of 1,1'-] dichloride
Palladium dichloromethane complex (0.1mmol), x-phos (0.4mmol), cesium carbonate (100mmol) and 1,4- dioxane/H2O
(60ml/10ml), dissolution, argon gas displacement, 105 DEG C of microwave reaction 90min, concentration, column chromatographic purifying obtain title compound.
ES:M/Z 564 [M+H]+。
Step 34- (dibenzo [b, d] thiophene -4- base) -6- (4- aminophenyl)-N- (2- methyl -4H- chromene -4- ketone
Base) -1,3,5- triazine -2- amine preparation
Weigh step 2 gains 4- (dibenzo [b, d] thiophene -4- base) -6- (4- nitrobenzophenone)-N- (2- methyl -4H-
Chromene -4- ketone group) -1,3,5-triazines -2- amine (1mmol), 10%Pd-C (10mg) in reaction flask, be added 15ml methanol, 1
A normal atmosphere pressure, H21h is restored, reaction is stopped, title compound is concentrated in filtering, is directly used in next step.
ES:M/Z 534 [M+H]+。
Step 4 4- (dibenzo [b, d] thiophene -4- base) -6- (4- allyl amido phenyl)-N- (2- methyl -4H- color
Alkene -4- ketone group) -1,3,5- triazine -2- amine preparation
Weigh step 3 gains 4- (dibenzo [b, d] thiophene -4- base) -6- (4- aminophenyl)-N- (2- methyl -4H-
Chromene -4- ketone group) -1,3,5-triazines -2- amine (0.1mmol), diisopropylethylamine (0.3mmol) in reaction flask, be added
The dissolution of 15ml anhydrous methylene chloride, is slowly dropped into methylene chloride (1ml) solution dissolved with allyl acyl chlorides (0.12mmol),
10min fully reacting, concentration, column chromatographic purifying obtain title compound.
1H NMR(600MHz,CDCl3) (δ, ppm): 10.12 (s, 1H), 8.47~8.48 (m, 1H), 7.97~7.98 (m,
1H), 7.79~7.81 (m, 3H), 7.67~7.69 (m, 2H), 7.50~7.52 (m, 3H), 7.38~7.40 (m, 2H), 7.28
~7.30 (m, 1H), 7.07~7.09 (m, 2H), 6.48~6.50 (m, 1H), 6.01~6.03 (m, 1H), 5.55 (s, 1H),
5.50~5.52 (m, 1H), 4.89 (s, 1H), 4.47~4.50 (m, 1H), 3.06~3.08 (m, 2H), 2.81~2.83 (m,
2H), 2.01~2.03 (brs, 2H), 1.91~1.93 (brs, 1H)
ES:M/Z 588 [M+H]+。
5 4- of embodiment (dibenzo [b, d] thiophene -4- base) -6- (4- allyl amido phenyl)-N- (2- methyl -4H- color
Alkene -4- ketone group) -1,3,5- triazine -2- amine tartrate preparation
4 compound of embodiment (1.0mmol) is weighed in reaction flask, adds ethyl alcohol 10mL, at room temperature after stirring and dissolving, is added
Tartaric acid 0.5mmol, finishes, and flow back 0.5h, is cooled to room temperature, evaporating solvent under reduced pressure, and vacuum drying obtains titled at room temperature
Close object.
Embodiment 6:4- (dibenzo [b, d] thiophene -4- base) -6- (4- allyl amido phenyl)-N- (2- methyl -4H- color
Alkene -4- ketone group) -1,3,5- triazine -2- amine tartrate preparation
4 compound of embodiment (1.0mmol) is weighed in reaction flask, adds methanol 10mL, at room temperature after stirring and dissolving, is added
Tartaric acid 0.55mmol, finishes, and flow back 0.5h, is cooled to room temperature, evaporating solvent under reduced pressure, and vacuum drying obtains titled at room temperature
Close object.
Experimental example 1: biological activity determination
Compound prepares: the full-automatic microwell plate pretreatment system of POD810 is prepared the embodiment of the present invention 4 and embodiment 5
Compound be added in orifice plate, compound initial concentration is 100uM, and each compound does duplicate hole, 2 times of dilutions, 10 points.
The culture of cell: prostate gland cancer cell DU-145, human breast cancer cell MDA-MB-468 are used contain 15% tire respectively
The RPMI-1640 culture medium of cow's serum (FBS) is cultivated in 37 degree of incubators, and logarithmic growth phase cell is for testing.
The experiment of MTT cells viability: prostate gland cancer cell DU-145, human breast cancer cell MDA-MB-468 are inoculated with respectively
(5-10 × 10 in 96 orifice plates4Cells/well), 48h is handled with the compound of embodiment 5 and 6 respectively, 20 μ is added in every hole
L 3- (4,5- dimethylthiazole -2) -2,5- diphenyltetrazolium bromide bromide (MTT) hatches 4h, and 100 μ l in every hole is then added
DMSO sets low-speed oscillation 10min on shaking table, dissolves crystal sufficiently.It is measured at enzyme-linked immunosorbent assay instrument OD 490nm each
The light absorption value in hole handles to obtain homologous thread and IC using GraphPad Prism50Value, the results are shown in Table 1.
Table 1
The experimental results showed that the present invention is thin to the active MDA-MB-468 cell of STAT3, DU-145 with sustained activation
Born of the same parents have excellent inhibiting effect.
The water-soluble evaluation of experimental example 2
By pharmacopeia four water-soluble experiments in 2015, experimental result was shown in Table 2.
Table 2
| Compound | It is water-soluble |
| 5 compound of embodiment | 38.29mg/ml |
3 stability study of experimental example
Weigh 3 parts of 4- (dibenzo [b, d] thiophene -4- base) -6- (4- allyl amido phenyl)-N- (2- methyl -4H- color
Alkene -4- ketone group) -1,3,5-triazines -2- amine tartrate 1.0g, it is laid in culture dish respectively, 1 part of opening is placed in illumination illumination
To place under the conditions of 4500Lx ± 500Lx 3 months, 1 part of opening places 3 under the conditions of being placed in 75% relative humidity of room temperature (RH)
Month, 1 part of opening is placed 3 months under the conditions of being placed in 92.5% relative humidity of room temperature (RH), is sampled in the 0th, 1,2,3 month, examination
The variation of largest single impurity, total impurities, experimental result are shown in Table 3.
Table 3
Above-mentioned experimental result shows 4- of the invention (dibenzo [b, d] thiophene -4- base) -6- (4- acrylyl aminobenzene
Base)-N- (2- methyl -4H- chromene -4- ketone group) -1,3,5- triazine -2- amine tartrate have good chemical stability.
Claims (7)
1. a kind of taxol and dibenzo [b, d] thiophene-based STAT inhibitor tartrate drug combination compositions, comprising living
Property ingredient and pharmaceutically acceptable auxiliary material, it is characterised in that: active constituent hexichol as shown in taxol and formula (I)
And [b, d] thiophene-based STAT inhibitor tartrate forms, dibenzo shown in taxol and formula (I) in the active constituent
The mass ratio of [b, d] thiophene-based STAT inhibitor tartrate is (0.08-0.14): 1；Wherein, dibenzo shown in formula (I)
[b, d] thiophene-based STAT inhibitor tartrate, chemical formula are as follows:
2. a kind of taxol as described in claim 1 and dibenzo [b, d] thiophene-based STAT inhibitor tartrate joint are used
Pharmaceutical composition, it is characterised in that: 4- (dibenzo [b, d] thiophene -4- base) -6- (4- allyl amido phenyl)-N- (2- first
Base -4H- chromene -4- ketone group) -1,3,5-triazines -2- amine tartrate preparation method, comprising the following steps:
The compound of formula (1) is made in step a:2- hydroxy acetophenone acetylation；
Step b: the compound of formula (2) is made in the compound cyclization of formula (1)；
Step c: the compound of formula (3) is made in the compound bromo of formula (2)；
Step d: the compound amino of formula (3) replaces the compound that formula (4) are made；
The compound of formula (5) is made in step e:4- nitrobenzene methyl and biuret cyclization；
Step f: the compound of formula (6) is made in the compound chloro of formula (5)；
Step g: the compound of formula (6) reacts the compound that formula (7) are made with the compound of formula (4)；
Step h: the compound and 4- (4,4,5,5- tetramethyl -1,3,2- dioxolane borine) -9- oxo -9H- sulphur of formula (7)
Miscellaneous anthracene reacts the compound that formula (8) are made；
Step i: the compound reduction of formula (8) hydrogenates the compound that formula (9) are made；
Step j: the compound of formula (9) reacts the compound that formula (I) is made with acryloyl chloride；
Step k: the compound of formula (I) is reacted with tartaric acid is made formula (I) compound tartrate, and reaction route is as follows:
3. preparation method as claimed in claim 2, it is characterised in that: the solvent that formula (I) compound is reacted with tartaric acid is selected from
Alcohol, ketone or their mixture.
4. preparation method as claimed in claim 2, it is characterised in that: the solvent that formula (I) compound is reacted with tartaric acid is first
Alcohol or ethyl alcohol.
5. preparation method as claimed in claim 2, it is characterised in that: the molar ratio that formula (I) compound is reacted with tartaric acid is
About 1:0.5-0.55.
6. preparation method as claimed in claim 2, it is characterised in that: the molar ratio that formula (I) compound is reacted with tartaric acid is
About 1:0.5.
7. a kind of dibenzo [b, d] thiophene-based STAT inhibitor tartrate drug combination compositions, comprising active constituent and
Pharmaceutically acceptable auxiliary material, it is characterised in that: active constituent hexichol as shown in taxol, lenalidomide, formula (I)
And [b, d] thiophene-based STAT inhibitor tartrate forms, dibenzo shown in taxol and formula (I) in the active constituent
The mass ratio of [b, d] thiophene-based STAT inhibitor tartrate is (0.08-0.14): (0.08-0.12): 1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811283138.1A CN109200044A (en) | 2018-10-31 | 2018-10-31 | A kind of taxol and dibenzo [b, d] thiophene-based STAT inhibitor tartrate drug combination compositions |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811283138.1A CN109200044A (en) | 2018-10-31 | 2018-10-31 | A kind of taxol and dibenzo [b, d] thiophene-based STAT inhibitor tartrate drug combination compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109200044A true CN109200044A (en) | 2019-01-15 |
Family
ID=64997664
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811283138.1A Withdrawn CN109200044A (en) | 2018-10-31 | 2018-10-31 | A kind of taxol and dibenzo [b, d] thiophene-based STAT inhibitor tartrate drug combination compositions |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109200044A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070060521A1 (en) * | 1999-01-27 | 2007-03-15 | The University Of South Florida, A Public Corporation Of The State Of Florida Corporation | Inhibition of STAT3 signal transduction for human cancer therapy |
| CN101854802A (en) * | 2007-09-10 | 2010-10-06 | 波士顿生物医药公司 | Novel compositions and methods for cancer treatment |
| CN102884062A (en) * | 2009-12-23 | 2013-01-16 | 嘉世高制药公司 | Aminopyrimidine kinase inhibitors |
| US20140045908A1 (en) * | 2011-02-25 | 2014-02-13 | Synta Pharmaceuticals Corp. | Hsp90 inhibitory compounds in treating jak/stat signaling-mediated cancers |
-
2018
- 2018-10-31 CN CN201811283138.1A patent/CN109200044A/en not_active Withdrawn
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070060521A1 (en) * | 1999-01-27 | 2007-03-15 | The University Of South Florida, A Public Corporation Of The State Of Florida Corporation | Inhibition of STAT3 signal transduction for human cancer therapy |
| CN101854802A (en) * | 2007-09-10 | 2010-10-06 | 波士顿生物医药公司 | Novel compositions and methods for cancer treatment |
| CN102884062A (en) * | 2009-12-23 | 2013-01-16 | 嘉世高制药公司 | Aminopyrimidine kinase inhibitors |
| US20140045908A1 (en) * | 2011-02-25 | 2014-02-13 | Synta Pharmaceuticals Corp. | Hsp90 inhibitory compounds in treating jak/stat signaling-mediated cancers |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6267397B1 (en) | Pharmaceutical compositions containing substituted polycyclic pyridone derivatives and prodrugs thereof | |
| UA123010C2 (en) | Cot modulators and methods of use thereof | |
| CN104230952A (en) | Compound containing pyrimidine skeleton, and preparation method and use of compound | |
| JP7301856B2 (en) | Indoleamine-2,3-dioxygenase inhibitors and methods of preparation and use thereof | |
| WO2014169882A2 (en) | Benzimidazole-type compound exhibiting anti-tumor activity, preparation method and use thereof | |
| CN109200044A (en) | A kind of taxol and dibenzo [b, d] thiophene-based STAT inhibitor tartrate drug combination compositions | |
| CN109336876A (en) | Tartrate of dibenzo [b, d] thiophene-based STAT3 inhibitor and preparation method thereof and purposes | |
| CN109336877A (en) | Mesylate of dibenzo [b, d] thiophene-based STAT3 inhibitor and preparation method thereof and purposes | |
| CN107614502A (en) | The preparation and application of kinase inhibitor | |
| CN109180657A (en) | The preparation method of STAT3 inhibitor | |
| KR20240004634A (en) | Tricyclic ubiquitin-specific protease 1 inhibitors and uses thereof | |
| CN110167554A (en) | A kind of compound and its preparation method and application with antitumaous effect | |
| CN104926804B (en) | One kind has compound, the preparation method and use of antitumor action | |
| CN109966297A (en) | A kind of taxol and carbazoles STAT inhibitor maleate crystal form I drug combination compositions | |
| CN109288846A (en) | A kind of taxol and carbazoles STAT3 inhibitor crystal form A drug combination compositions | |
| CN109336869A (en) | A kind of mesylate of STAT3 inhibitor and preparation method thereof and purposes | |
| CN109288845A (en) | A kind of carbazoles STAT inhibitor maleate crystal form II drug combination compositions and preparation method thereof | |
| CN109331004A (en) | A kind of taxol and dibenzo [b, d] thiophene-based STAT inhibitor mesylate A crystal form drug combination compositions | |
| CN109336870A (en) | Carbazoles STAT3 inhibitor crystal form I and preparation method thereof | |
| CN109223758A (en) | A kind of taxol and fluorenes class STAT3 inhibitor drug combination compositions | |
| CN109369628A (en) | Carbazoles STAT3 inhibitor crystal form II and preparation method thereof | |
| CN109200052A (en) | A kind of taxol and Fluorenone class STAT3 inhibitor drug combination compositions | |
| CN108947961B (en) | Indazole derivative and preparation method and application thereof | |
| CN109336871A (en) | A kind of maleate of STAT3 inhibitor and preparation method thereof and purposes | |
| CN109172563A (en) | A kind of thioxanthene ketone class taxol and STAT3 inhibitor drug combination compositions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20190115 |